Xiaoqiong Tang

Univariate and Multivariable Analysis of PFS in Overall

Kaplan–Meier survival curves comparing CR and non-CR patients by disease subtype

Univariate and Multivariate Logistic Regression Analysis of CR in Overall

Sites of CNS and other tissue involvement in SCNSL patients

Prior and Glofitamab Treatments

Characteristics and Response of patients with glofitamab monotherapy or combination therapy

Characteristics in CR and non-CR patients

Relapsed or refractory central nervous system lymphoma (R/R CNSL) has limited treatment options. This multicenter retrospective study enrolled 84 consecutive patients with R/R CNSL [median age, 59 years; median of 2.5 prior lines of therapy; 53 primary CNSL (PCNSL) and 31 secondary CNSL (SCNSL)] to evaluate the efficacy and safety profiles of glofitamab therapy. For PCNSL, the objective response rate (ORR) was 88% and complete response rate (CRR) was 59% with glofitamab monotherapy (n = 32) and 100% and 81% with combination therapy (n = 21), respectively. For SCNSL, ORR and CRR were 88% and 75% with glofitamab monotherapy (n = 8) and 91% and 65% with combination therapy (n = 23). At 14.7 months of follow-up, median progression-free survival was 19.5 months for PCNSL and 13.5 months for SCNSL. Cytokine release syndrome occurred in 40% (all grades 1–2) of patients, and immune effector cell–associated neurotoxicity syndrome occurred in 8%. Glofitamab-based therapy demonstrated substantial activity with manageable toxicity in this study, offering a promising treatment paradigm for patients with R/R CNSL. Significance: Effective therapies are urgently needed for R/R CNSL. Glofitamab-based therapy demonstrated high response rates in PCNSL (ORR, 92%; CRR, 68%) and SCNSL (ORR, 90%; CRR, 68%) with manageable toxicity in 84 consecutive, heavily pretreated patients, establishing a promising treatment option for this high-risk population.